Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 13/20 | 0.55 |
| ▸ | MET | P08581 | 13/20 | 0.55 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709454 | 0.95 | TYRO3 (0.57) | AXLMETTYRO3MERTKKDM4E | |
| SCHEMBL18044583 | 0.95 | TYRO3 (0.55) | AXLMETTYRO3MERTKKDM4E | |
| SCHEMBL18044591 | 0.91 | ALDH1A1 (0.56) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL18044552 | 0.90 | MET (0.53) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL18044728 | 0.89 | MET (0.52) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL18044543 | 0.88 | MET (0.55) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL18044549 | 0.88 | AXL (0.66) | AXLMETTYRO3MERTKMAPT | |
| SCHEMBL18044526 | 0.88 | TYRO3 (0.48) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL18044702 | 0.88 | MET (0.51) | AXLMETTYRO3MERTKFLT3 | |
| SCHEMBL16709489 | 0.86 | ALDH1A1 (0.63) | AXLMETTYRO3MERTKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | AXL 1/4885MET 398/4885TYRO3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.